Commentary

ACTRAP: A Conceptual Proposal for In Situ Discovery of Anticancer Natural Products

Maxwel Adriano Abegg[1]

1. Institute of Exact Sciences and Technology (ICET), Graduate Program in Science, Technology and Health (PPGCTS), Federal University of Amazonas (UFAM), Brazil

The discovery of anticancer natural products often fails to capture metabolites induced only under native environmental cues. This article presents a conceptual proposal—ACTRAP—for a field-deployable platform that integrates in situ cultivation of environmental microbiota with a hydrogel-embedded tumor-cell reporter for endpoint viability readouts. Unlike classical co-culture systems designed for incubators and plate readers, ACTRAP is envisioned as a sealed, passively operated stack that couples a cultivation array to a tumor-cell biosensor through semipermeable membranes, enabling functional triage prior to laboratory isolation. We do not report any prototype, experiments, or practical tests; no empirical data are presented. Instead, we (i) position the concept relative to benchtop co-culture platforms (Transwell inserts, BioMe microplates, Cerillo Duet) and to in situ cultivation devices (diffusion chambers, iChip/HFMC); (ii) detail the proposed device geometry, membrane stack, reporter biology, and endpoint assays; and (iii) outline a staged, forward-looking validation plan addressing viability, sensitivity, and field robustness. The intended purpose is to prioritize microcultures that may produce cytotoxic metabolites under environmental conditions, thereby guiding subsequent dereplication and characterization once prototypes are built and tested.

Corresponding author: Maxwel Adriano Abegg, maxabegg@gmail.com

1. Introduction

Natural products supply a substantial share of oncology drugs and remain a cornerstone for new chemotypes [1][2]. Microorganisms—especially actinomycetes—continue to yield structurally diverse and mechanistically novel metabolites with antitumor potential [3][4]. Yet the biosynthetic potential of

environmental microbiomes remains underexploited because most taxa are not readily cultivated ex situ, and many biosynthetic gene clusters fall silent under artificial conditions [5][6][7].

Technologies that expose microorganisms to native physicochemical cues—notably diffusion chambers and the iChip family—have unlocked the growth of previously uncultured organisms [8][9]. In parallel, metabolomics has matured as a powerful tool to annotate small molecules in complex matrices, but it does not by itself establish a biological effect during environmental incubation [10].

ACTRAP addresses this gap by pairing in situ cultivation with an embedded tumor-cell reporter that provides an endpoint cytotoxicity readout while environmental cues are still present. The lower compartment contains a pre-equilibrated tumor-cell biosensor; the upper compartment cultivates environmental inocula behind microbe-tight, diffusion-permissive barriers. Molecular transfer is unidirectional by design (cultivation → reporter), and a single terminal assay (ATP luminescence as primary; resazurin as secondary) flags wells for priority isolation. By integrating environmental growth and functional selection, ACTRAP aims to surface metabolites that are exclusively or preferentially produced in situ [1][2][3][4][8][9].

2. Positioning: Not a Co-Culture System

Bench platforms such as Transwell inserts, BioMe microplates, and the Cerillo Duet are optimized for controlled incubators and plate-reader analytics to study reciprocal interactions between two cell populations over time [11]. ACTRAP, in contrast, is a field-exposed functional biosensor: the reporter layer is not a co-growing partner but a receiver-only, hydrogel-embedded tumor-cell layer that converts exposure to a viability signal at a single endpoint. Mechanistic immunology paradigms such as antibody-dependent cell-mediated cytotoxicity (ADCC) illustrate how functional readouts can be decoupled from growth per se—yet ACTRAP intentionally avoids immune-effector dependencies and focuses on tumor-cell viability as a universal proxy for cytotoxic metabolite production [12]. Cell-death modes relevant to anticancer discovery (apoptosis, necrosis, pyroptosis) may contribute to the observed endpoint and can be further resolved with pathway-specific reporters in future iterations [13].

3. Device Architecture and Operating Principle

Geometry and assembly. The platform uses two perforated polycarbonate “honeycomb” plates (nominal example: 25 × 25 cm, ~238 hexagonal wells of 17 mm inner diameter; 5 mm plate and wall thickness)

clamped between a solid base and a microbe-tight, diffusion-permissive top film via corner bolts and gaskets. The upper plate hosts environmental inocula and semi-solid medium; each well is sealed superiorly with a 0.2 µm track-etched film to allow gas/solute exchange while preventing cell escape. A graded-MWCO interlayer (e.g., stacked dialysis membranes ≈2–5 kDa) separates the upper cultivation array from the lower plate, which contains the tumor-cell hydrogel reporter; a dark base improves optical signal-to-noise and limits phototoxicity. This layout is designed for passive, field deployment with endpoint readout.

Unidirectional mass transfer. Membranes are selected to favor downward diffusion of small metabolites while suppressing the reflux of macromolecules toward the reporter. If the accumulation of reporter-derived by-products is problematic, the solid base can be swapped for a dark, track-etched membrane to vent outward.

Environmental deployment. The assembled device is sealed and placed in soil/sediment niches under shade for 7–15 days (optionally up to 30 days); a top 0.2 µm track-etched film provides gas exchange while excluding microbes/particulates. Internal compression and hydrophobic surface treatments enhance sealing and fouling resistance [14].

4. Reporter Biology, Media, and Assays

Hydrogel-embedded tumor cells. Robust lines such as MCF-7 are embedded in alginate or hybrid hydrogels. Three-dimensional matrices improve physiologic relevance and resilience during prolonged exposure [15][16][17][18]. To avoid dependence on a CO_2 incubator during environmental deployment, the reporter is formulated with CO_2-independent media; conservative first-pass exposure windows of 7–15 days minimize pH/O_2 drift and confluence-driven artifacts [16][18].

Primary readout—ATP luminescence. CellTiter-Glo® provides sensitive, broad-range endpoint viability suitable for high-throughput formats and prolonged exposures [19].

Secondary readout—resazurin. Alamar Blue offers low-cost color/fluorescence triage when applied once at the endpoint to avoid redox carryover [20]. As needed, complementary assays (e.g., SRB, MTT/XTT) can be used for orthogonal confirmation [21][22]. A comparative overview of endpoint assays, including sensitivity, interferences, and field suitability, is provided in Table 1.

Method	Signal Type	Advantages	Limitations	References
ATP (CellTiter-Glo®)	Luminescent	Quantitative; highly sensitive; widely validated	Requires reagent addition; single-use endpoint assay	Promega, 2022; Lee et al., 2008; Ramirez et al., 2016
Resazurin (Alamar Blue)	Colorimetric / Fluorescent	Non-toxic; stable; compatible with visual readout	Susceptible to interference; reduced precision over time	Rampersad, 2012; Vichai & Kirtikara, 2006
Caspase 3/7 Substrates	Fluorescent	Apoptosis-specific; useful in mechanism studies	Requires pre-loading; signal decay; limited shelf life	Taabazuing et al., 2017
MTT/XTT (Tetrazolium dyes)	Colorimetric	Quantitative; well-established	Requires reagent addition and cell lysis	Vichai & Kirtikara, 2006
Calcein-AM / CellTracker™	Fluorescent	High signal from viable cells	Dye efflux; potential cytotoxicity	Chung et al., 2014
Electrochemical Impedance	Electrical (label-free)	Continuous monitoring; no labeling needed	Requires electrodes, signal capture, and power supply	Kokkinos et al., 2016

Table 1. Comparison of Cell Viability and Detection Assays

Controls and QC. Arrays incorporate blanks (limit-of-blank estimation), sterile-medium negatives, reference cytotoxins (positives), and integrity tracers confined to the cultivation side. Where relevant, electrochemical or optical sensors may be integrated as non-cellular sentinels in dedicated wells, leveraging advances in electrochemical immunosensors [23].

5. Practical Prototyping and Validation Plan

Stage A — Bench prototype (incubator). Assemble mini-ACTRAPs using commercial membranes; apply environmental extracts or model metabolites to the cultivation side; embed MCF-7 in hydrogels on the reporter side. Endpoints at days 7 and 15: ATP luminescence (primary) and single resazurin snapshot

(secondary). Outcomes: signal-to-noise; LOB/LOD/functional LOQ via serial cytotoxin titrations; leak-test acceptance [11][19][20].

Stage B — CO_2-independent viability envelope. Repeat Stage A entirely under ambient air using CO_2-independent medium; monitor pH, morphology, and ATP signal to confirm viability without CO_2 [16][15].

Stage C — In situ pilot. Deploy sealed units in shaded environmental niches (25–30 °C). Retrieve at day 7/15 and assay endpoints; correlate "hits" to paired cultivation wells for microbe isolation, followed by LC-MS dereplication [8][9][4].

Stage D — Mechanism-oriented variants. Embed reporter lines indicating DNA damage or mitochondrial stress to differentiate cytostatic vs. cytotoxic profiles while retaining endpoint simplicity [13].

6. Anticipated Advantages and Use Cases

Functional selection upstream of isolation. Early, in situ triage may reduce unproductive isolations and prioritize ecologically induced metabolites [1][2][4].

Compatibility with uncultured taxa. ACTRAP leverages in situ cues known to unlock the growth of "unculturable" organisms [8][9][6].

Low instrumentation burden. Passive deployment and single-endpoint chemistry suit remote settings and lean laboratories [19][20].

Modularity. Membrane MWCOs, surface treatments, media, reporter lines, and assay chemistries are swappable to target different mechanisms or resilience requirements [23][14].

Ecological linkage. Functional positives can be directly tied back to their originating microcultures in the array, strengthening source–producer inference [7][4].

7. Limitations and Risk Mitigation

Physiological drift in passive conditions. Conservative exposure windows (7–15 days), shaded enclosures, and CO_2-independent media mitigate pH/O_2 drift; longer deployments may incorporate micro-refresh through pre-sealed septa [16][18].

Matrix interference. Colored or redox-active compounds may perturb resazurin; thus, ATP luminescence is primary, and SRB/MTT can serve as orthogonal checks [20][21][22].

Membrane fouling and leakage. Redundant sealing (gaskets + compression), hydrophobic/anti-wetting coatings, and leak tracers limit failure modes [14].

Biological confounders. Endocrine responsiveness of MCF-7 and stress-tolerant persister states can modulate endpoint signals; these are mitigated by appropriate controls and, where needed, alternate reporter lines [24][25].

Scope. ACTRAP prioritizes cytotoxic activity; immunologic mechanisms (e.g., ADCC) are out of scope for the current configuration but could be modeled separately if immune effectors are introduced [12].

8. Discussion

By coupling in situ cultivation with an embedded tumor-cell reporter, ACTRAP aims to detect biologically active metabolites under the very environmental conditions that elicit them—an axis that culturomics and metabolomics alone cannot resolve [10][4]. The approach complements established growth-enabling devices (diffusion chambers, iChip/HFMC) by adding an on-board functional readout, thereby narrowing the search space before isolation and chemical work-up [8][9][26]. Three-dimensional matrices and hydrogel scaffolds provide the physiological robustness needed for endpoint viability under passive deployment [15][16][17][18]. Where redox or color interferences are expected, orthogonal assays (SRB/MTT) or non-cellular electrochemical sentinels can be layered to maintain specificity [21][22][23].

Although only a fraction of positive wells will advance to confirmed leads, early functional selection can improve hit-to-lead efficiency and illuminate ecological contexts that shape metabolite expression [1][2][7][4]. The staged validation plan directly addresses reviewer concerns about viability windows, assay sensitivity, and device robustness, while keeping the system modular and reproducible with off-the-shelf components [19][20][14]. Ultimately, ACTRAP is best viewed not as a co-culture platform but as in situ cultivation with an embedded functional reporter—a complementary tool in the natural-product discovery toolbox.

9. Conclusion

ACTRAP operationalizes a simple principle: when both growth and metabolite induction depend on environmental context, functional screening should occur while that context is present. The described architecture, assays, and validation stages render the concept testable now, with the potential to surface anticancer metabolites that would be missed by purely ex situ pipelines [1][3][4][6][8][9].

Figures



Figure 1. Exploded schematic of the ACTRAP stack. From bottom to top: (1) solid dark base; (2) lower plate containing hydrogel-embedded tumor-cell reporter; (3) graded-MWCO inter-membrane assembly; (4) upper cultivation plate with environmental inocula; (5) external 0.2 µm track-etched film. Corner bolts and gaskets provide compression sealing.



Figure 2. Plan view of the perforated plate. Example dimensions: 25 × 25 cm footprint; hexagonal wells ~17 mm inner diameter; plate and wall thickness ~5 mm; four corner bolt holes. Each plate can function as a cultivation or detection module in the stacked assembly.

Authors' Note

This manuscript was prepared with assistance from OpenAI's ChatGPT-5 for language refinement and figure drafting, strictly according to the author's technical inputs and specifications. The model did not perform data analysis or make independent scientific judgments. All scientific content, conceptual

development, and device design are original and remain the sole responsibility of the author. Inquiries and collaborations for prototyping the ACTRAP device are welcome.

References

1. ^a ^b ^c ^d ^e *Cragg GM, Grothaus PG, Newman DJ (2009). "Impact of Natural Products on Developing New Anti cancer Agents." Chem Rev.* **109**(7):3012–3043.
2. ^a ^b ^c ^d *Newman DJ, Cragg GM (2020). "Natural Products as Sources of New Drugs Over the Nearly Four Dec ades from 01/1981 to 09/2019." J Nat Prod.* **83**(3):770–803.
3. ^a ^b ^c *Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q (2022). "Natural Products as Anticancer Agents: Current Status and Future Perspectives." Molecules.* **27**(23):8367.
4. ^a ^b ^c ^d ^e ^f ^g ^h *Schniete JK, Fernández-Martínez LT (2024). "Natural Product Discovery in Soil Actinomycete s: Unlocking Their Potential Within an Ecological Context." Curr Opin Microbiol.* **79**:102487.
5. ^^ *Kapinusová K, Prudnikova T, Sedlářová M, et al. (2023). "Shedding Light on the Composition of Extreme Microbial Dark Matter: Alternative Approaches for Culturing Extremophiles." Front Microbiol.* **14**:1167718.
6. ^a ^b ^c *Stewart EJ (2012). "Growing Unculturable Bacteria." J Bacteriol.* **194**(16):4151–4160.
7. ^a ^b ^c *Lewis K, Epstein S, D'Onofrio A, Ling LL (2010). "Uncultured Microorganisms as a Source of Secondary Metabolites." J Antibiot (Tokyo).* **63**(8):468–476.
8. ^a ^b ^c ^d ^e ^f *Kaeberlein T, Lewis K, Epstein SS (2002). "Isolating "Uncultivable" Microorganisms in Pure Cultu re in a Simulated Natural Environment." Science.* **296**(5570):1127–1129.
9. ^a ^b ^c ^d ^e ^f *Nichols D, Cahoon N, Trakhtenberg EM, et al. (2010). "Use of iChip for High-Throughput in Situ C ultivation of "Uncultivable" Microbial Species." Appl Environ Microbiol.* **76**(8):2445–2450.
10. ^a ^b *Choi YH, Jang YP, Frédérich M (2023). "Editorial: Applications of Metabolomics to the Discovery of Biomo lecules from Natural Products." Front Mol Biosci.* **10**:1190730.
11. ^a ^b *Chaudhry G, Zeenia, Safdar N, Begum S, Akim AM, Sung YY, Muhammad TST (2024). "Cytotoxicity Assa ys for Cancer Drug Screening: Methodological Insights and Considerations for Reliable Assessment in Drug Discovery." Braz J Biol.* **84**:e284409.
12. ^a ^b *Chung S, Lin Y-L, Reed C, et al. (2014). "Characterization of in Vitro Antibody-Dependent Cell-Mediated Cytotoxicity Activity of Therapeutic Antibodies—Impact of Effector Cells." J Immunol Methods.* **407**:63–75.
13. ^a ^b *Taabazuing CY, Okondo MC, Bachovchin DA (2017). "Pyroptosis and Apoptosis Pathways Engage in Bidi rectional Crosstalk in Monocytes and Macrophages." Cell Chem Biol.* **24**(4):507–514.

14. a, b, c, d Zhang Y, Liu T, Kang J, Guo N, Guo Z, Chen J, Yin Y (2022). "Design of Multi-Functional Superhydrophobic Coating Via Bacterium-Induced Hierarchically Structured Minerals on Steel Surface." Front Microbiol. **13**:934966.

15. a, b, c Lee J, Cuddihy MJ, Kotov NA (2008). "Three-Dimensional Cell Culture Matrices: State of the Art." Tissue Eng Part B Rev. **14**(1):61–86.

16. a, b, c, d, e Zhu J, Marchant RE (2011). "Design Properties of Hydrogel Tissue-Engineering Scaffolds." Expert Rev Med Devices. **8**(5):607–626.

17. a, b Dell AC, Wagner G, Own J, Geibel JP (2022). "3D Bioprinting Using Hydrogels: Cell Inks and Tissue Engineering Applications." Pharmaceutics. **14**(12):2596.

18. a, b, c, d Comşa S, Cîmpean AM, Raica M (2015). "The Story of MCF-7 Breast Cancer Cell Line: 40 Years of Experience in Research." Anticancer Res. **35**(6):3147–3154.

19. a, b, c, d Promega Corporation (2022). "CellTiter-Glo® Luminescent Cell Viability Assay—Technical Bulletin TB288." Promega. Madison, WI.

20. a, b, c, d, e Rampersad SN (2012). "Multiple Applications of Alamar Blue as an Indicator of Metabolic Function and Cellular Health in Cell Viability Bioassays." Sensors (Basel). **12**(9):12347–12360.

21. a, b, c Vichai V, Kirtikara K (2006). "Sulforhodamine B Colorimetric Assay for Cytotoxicity Screening." Nat Protoc. **1**(3):1112–1116.

22. a, b, c Bahuguna A, Khan I, Bajpai VK, Kang SC (2017). "MTT Assay to Evaluate the Cytotoxic Potential of a Drug." Bangladesh J Pharmacol. **12**(2):115–118.

23. a, b, c Kokkinos C, Economou A, Prodromidis MI (2016). "Electrochemical Immunosensors: Critical Survey of Different Architectures and Transduction Strategies." TrAC Trends Anal Chem. **79**:88–105.

24. ^ Lewis JS, Jordan VC (2005). "Selective Estrogen Receptor Modulators (SERMs): Mechanisms of Anticarcinogenesis and Drug Resistance." Mutat Res. **591**(1–2):247–263.

25. ^ Ramirez M, Rajaram S, Steininger RJ, et al. (2016). "Diverse Drug-Resistance Mechanisms Can Emerge from Drug-Tolerant Cancer Persister Cells." Nat Commun. **7**(1):10690.

26. ^ Epstein SS (2022). "Methods for Discovery of Antimicrobial Compounds." US Patent Application US20220049282A1. Feb 17.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.